FDA clears Gain Therapeutics' IND for Parkinson's candidate GT-02287, enabling U.S. Phase 2 trial starting in 3Q26
https://finviz.com/stock?t=GANX&p=d
Note: Only a member of this blog may post a comment.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.